Greetings, and welcome to Forian Inc. Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal comments and webcast. Participating today from Forian are Max Wygod, Executive Chairman and Chief Executive Officer; and Michael Vesey, Chief Financial Officer. Before we begin, I'd like to remind you that management's remarks today may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by those forward-looking statements due to a variety of important factors including those discussed in the Risk Factors section of the company's annual report on Form 10-K filed with the SEC on March 27, 2023. In particular, management will discuss an estimate of its full year 2023 revenue outlook as of today. Estimating financial performance accurately for future performance is difficult as it involves assumptions and internal estimates that may prove to be incorrect and is based on plans and circumstances that may change. There is, therefore, a significant risk that actual results could differ materially from the outlook provided today. Any forward-looking statements made on the call today represent the company's views as of this date and the company under takes no obligation to update them except as required by law. Words such as estimate, projected, expect, anticipate, forecast, plan, intend, believe, seek, may, will, should, future, propose and variations of these words or similar expressions or versions of such words or expressions are intended to identify forward-looking statements These statements include, but are not limited to, statements regarding future growth, anticipated performance and prospects. Today's presenters will also refer to certain non-GAAP financial measures on our call, such as adjusted EBITDA, which the company believes may be important to investors to assess its operating performance and should be considered as supplement to and not a substitute for financial measures prepared in accordance with GAAP. A reconciliation of the comparable GAAP metric can be found in today's press release and webcast, both of which are available on the company's website. Those numbers are unaudited and any statements regarding the company's anticipated performance may be subject to change, including as a result of risks discussed in the Risk Factors section of the company's annual report on Form 10-K filed with the SEC on March 27, 2023. Today's call and webcast is being recorded. A copy of the recording webcast as well as the full transcript and copies of today's press release and SEC filings will be available at florian.com/investors. I am now pleased to introduce the company's Executive Chairman and Interim Chief Executive Officer, Max Wygod. Sir, you may begin.

Good afternoon, and welcome. I thank all of you for joining us today to review Forian's 2022 fourth quarter and fiscal year financial and business performance. I am pleased to share that we had another strong fiscal quarter with improvements in all key metrics. On today's call, I will review our fourth quarter and full year results, offer some perspective on Forian's business as we look forward as a healthcare information focused company following the recent divestiture of our cannabis industry software assets, and then Mike will discuss our financial performance. In 2022, Forian provided innovative software solutions and predictive analytics to optimize the operational, clinical and financial performance of our healthcare, cannabis and government customers. We are pleased to have delivered strong fourth quarter results on both the top- and bottom-lines. Our total fourth quarter revenue was $7.9 million, which represents 37% year-over-year growth. Our net loss for the quarter was $3.6 million and our adjusted EBITDA loss was $0.9 million, which translates into a 56% and 94% improvements year-over-year, respectively. For the full year 2022, our revenue of $28 million exceeded the high end of our guidance range of $27 million, representing 66% year-over-year growth driven by our healthcare information offerings. Our net loss for the year was $26 million and our adjusted EBITDA loss was $9.7 million, which translates into 2% and 36% improvements year-over-year, respectively. Before diving into the fourth quarter in more detail, I want to first acknowledge despite facing challenging macroeconomic conditions, the notable accomplishments we worked on throughout 2022. First, as previously announced in February of this year, we completed the strategic divestiture of our cannabis software operating subsidiary, BioTrack, on February 10, for $30 million in cash proceeds, which has enabled us to streamline our operations and dedicate more resources to our…

Thanks, Max. Today, I will provide an overview of Forian's financial results for the quarter ended December 31, 2022. As previously disclosed in our SEC filings, Forian completed the business combination of Helix Technologies and MOR Analytics on March 02, 2021. As a result, the operations of Helix are included in our financial results beginning March 02, 2021. The press release issued today presents Forian's fourth quarter 2021 and 2022 financial results on a GAAP basis. As in prior quarters, we have also reported adjusted EBITDA, which management uses as a measure to track the performance of the business. As noted, the press release and these presentation materials include a detailed reconciliation of adjusted EBITDA to net loss. Our consolidated revenues of $7.9 million for the quarter were up $2.2 million compared to the prior year. As in prior quarters, our year-over-year growth was driven by healthcare information products, which increased $1.9 million or 64% over the same quarter last year to $5 million. In many cases, our information contracts provide for continuing information deliverables to our customers over a multi-year period, providing a predictable recurring revenue stream. As a result, we have seen sequential increases in our healthcare revenue in each quarter since we began porting as a public company resulting from both new customers and sales of new products to our existing customer base. Net loss for the fourth quarter decreased $5.4 million from the same quarter last year to $3.6 million. The decrease in net loss was primarily driven by a decrease in loss from operations of $4.5 million, partially offset by changes in other income items such as interest, foreign currency related impacts and mark to market adjustments for warrants. The improvement in loss from operations resulted from the $2.2 million of revenue growth discussed above,…

Thank you. [Operator Instructions] I will turn the call back to Max to see if there are any questions from the web.

Yes. Thank you. Seems to be two questions coming in. The first is, what key differences do you see post the BioTrack divestiture? Well, there are a few points. First, we are now solely focused in healthcare information. Secondly, our overall size is reduced to less than 40 employees. And lastly, our opportunity to partner with certain healthcare and life science customers and vendors is no longer limited by our prior cannabis software business. I would say those are the key immediate differences we see so far. The second question is, what visibility do you have into reaching your adjusted EBITDA positivity? As we said, we are a subscription-based revenue model business. And we are coming into 2023 with a large amount of our contracted revenue. Based off of our current estimates, we have a projected -- we have projected achieving positive adjusted EBITDA in the second half of 2023. As an emerging growth company, our goal is to build long-term value. We believe we can do that organically. However, if we are in position to take advantage of any new opportunities or investments that further differentiate and drive share value, we will prudently evaluate those opportunities and the respective effects on our future P&L. Again, our priority remains on the long-term business of our company. Those are the only two questions I see coming in.

Thank you. One moment for our Q&A from the phones for our next question please. And it comes from the line of Eric Martinuzzi with Lake Street Capital Markets. Please proceed.

Yeah, congratulations on Q4 as well as getting the BioTrack transaction done. I know that was -- the effort there was substantial, and looks like you got a good price for it with the $30 million of cash. I wanted to ask you about the stub period that we're dealing with here. You said it's going to be treated as a -- BioTrack will be treated as a discontinued operation. Do you have a 2022 adjusted EBITDA kind of ex BioTrack, or you just -- really just got the revenue number there for 2022 on the health information side?

Yeah. Hey, Eric. It's Mike. The short answer is, we don't have a 2022 adjusted EBITDA number. But I think there's two places I can guide you to get the information you need. First one is on the revenue. We added a supplemental schedule in the press release, which separates the BioTrack revenue from the healthcare business revenue for the fourth quarter and for the year. So, I think you could pretty much pick up the run rate revenues of close to $5 million for healthcare in Q4 and then do your projections on how you think that will behave in the next year. In terms of operating expenses, the best thing to do there is we had about $11.3 million of operating expenses for Q4. And as we have discussed in the past, the BioTrack business was kind of a steady state business. So, if you just take the numbers from our nine-month pro formas and take essentially one quarter's worth of the run rate expenses, that was $4.4 million. So, we have $11.3 million of run rate expenses in Q4 2022. You back out the $4.4 million, which is attributable to BioTrack, that leaves about $6.9 million for the remaining business. We also gave you the stock-based compensation in that number, which is about $1.6 million. If you add that back, you'll get about $5.3 million run rate expenses attributable to the rest of the business. So, beside for all that, what it leaves you with is a business that has about $5 million run rate revenues, call it between $5 million and $5.5 million run rate expenses once we get through the Q1 cleanup, okay, because Q1 will be a transitionary period. And I think that's the best thing to work with going forward. The reason the pro -- direct pro formas I don't think would give you the right value is that, as you know, we made some other changes to our business structurally and the cost structure in addition to the divestiture of BioTrack itself. So, I think by just putting the pro forma number out there, I'm not sure would give you a better indicator than just going through that math.

Okay. I appreciate the nine-month analysis. As I look at the -- just the overall macro demand, you talk about there's headwinds in the kind of the customer the -- your installed base of customers as well as prospects and yet you're putting up terrific numbers here and you've given an outlook for 25% to 37% growth. Just kind of walk me through the different areas of the market that you serve, biopharm, med device, CRO. Can you address demand from each of those?

Sure. This is Max again, Eric. I think the easiest way to look at it, what's affected by kind of macroeconomic condition is really the size of the companies. So, where we have channel partners and other types of companies that serve eventual life science companies that are generally smaller. They've been affected more by what's been happening than the larger medtech or pharma industries. We haven't seen a slowdown in the CRO industry particularly, but it's really around either technical companies or other healthcare companies that are serving the bigger market kind of similar to how that technical -- tech companies are getting impacted by kind of the trends outside of healthcare.

Okay. And then, I think in your agreement with the BioTrack purchaser, you do continue to have access to the BioTrack data. Is that correct?

That's correct. We have access to the cannabinoid-based data, to kind of continue on our initial thesis of using it to evaluate outcomes on across the patient journey.

Okay. And then one of the numbers that I pay attention to in your financials is this contractually -- the committed kind of backlog that you talked about, I think you said in the -- for Q4 that committed contracted backlog was $38.8 million. Can you compare that to what it was a year ago for me?

Yes, Eric. It was about $20 million a year ago.

Okay. And then, the portion that's less than 12 months versus over 12 months of that, the $38.8 million, can you put that in the two buckets?

Yes, sure, I can. So, the -- of the $38.8 million, about $16.6 million we'll be recognizing in the next 12 months.

Okay. All right. Okay. That covers my questions. Congrats on the quarter, and good luck on the new more focused business.

Thank you.

Thank you, Eric.

Thank you. [Operator Instructions] I don't see any further questions in the queue. Ladies and gentlemen, with that, we conclude our program and Q&A session for today. Thank you for participating, and you may now disconnect.